Iovance Biotherapeutics (IOVA) 10-K2021 FY Annual report

Filed: 24 Feb 22, 5:14pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: acalabrutinib, Agenda, AKT, analog, Appellate, atezolizumab, Athena, Australia, balstilimab, Baseline, batch, bevacizumab, BeyondSpring, BIDMC, Bilinsky, Biomedicine, bioreactor, bona, cabozantinib, chemo, comprise, condensed, constantly, constitutionality, core, corroborated, CR, CRO, Daiichi, datopotamab, demographic, deruxtecan, differentiated, double, Eisai, encode, ernst, escalation, ESMO, expiry, feeder, fide, filtered, fit, Genmab, genomic, GRIT, harnessing, headquarter, heterogeneity, histology, ibrutinib, ICI, iCTC, ID, Igor, IL, immunomodulatory, Immunopharma, inactivated, inactivation, incubated, insertion, intolerance, invoicing, judgement, KSQ, lab, lessor, levatinib, Lyell, lymph, MCC, mechanism, MIA, Mirati, mission, multiforme, nearby, neoadjuvant, Neogene, Neoleukin, Nonqualified, Notably, Obsidian, oderparepvec, oncolytic, overhead, parent, path, pattern, Plymouth, portrayal, ransomware, rejuvenate, relatlimab, rep, Replimune, reprioritization, sanction, sanctioning, Sankyo, Sanofi, Seitter, signaling, Simplifying, sitravatinib, slowly, spectrum, static, strain, suggest, Surgery, systematic, temporally, thereon, tier, TILT, tisotumab, TIVDAK, TLR, transformational, Turnstone, vibostolimab, visit, vusolimogene, Weiser, Werewolf, workforce, zalifrelimab, Zeneca

Removed: AppTec, attaching, attestation, broken, capitalization, Chairman, committing, compensated, consult, controlled, costlier, cytolytic, deeming, defamation, denying, desist, disclosing, dismissed, disqualify, effecting, elimination, Excision, existence, explicitly, Extraction, feasible, Fischkoff, foot, Foundation, ineligible, Integrated, introduce, masthercell, MD, meaningfully, Northern, NY, offshore, Phil, possessing, prejudgment, prorated, purportedly, randomized, reevaluated, reincorporation, remission, repatriated, repatriation, repealing, rescission, restraining, retained, retrospective, software, stipulation, struck, sublease, taxation, Teradata, tolerate, transcription, UNAUDITED, unchanged, unconstitutional, unregistered, untimely, urelumab, validate, Vice

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated IOVA transcripts

IOVA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

I, Frederick G. Vogt, Ph.D., J.D., Interim Chief Executive Officer and President, and General Counsel, of Iovance Biotherapeutics, Inc. (Company), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

· the Annual Report on Form 10-K of the Company for the year ended December 31, 2021 (Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

· the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.

Date: February 24, 2022

	/s/ Frederick G. Vogt, Ph.D., J.D.
	Frederick G. Vogt, Ph.D., J.D.
	Interim Chief Executive Officer and President, and General Counsel (Principal Executive Officer)